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Technological advances in genomics are shifting 
the genetic testing paradigm, from testing targeted 
mutations in selected genes to testing whole genes and 
even whole genomes. These exciting developments 
raise numerous practical pitfalls and ethical issues. 
Two articles in this issue of the SAMJ address genetic testing for 
multifactorial diseases.[1,2]
Multifactorial diseases (MDs) are those caused by the interaction 
of multiple genetic and environmental risk factors, and cause a huge 
disease burden in South Africa (SA).[3] They include most ‘lifestyle 
diseases’, neuropsychiatric disorders, and cancer predispositions. 
Given the importance of MDs, detection of genetic predisposition is 
potentially attractive to facilitate prevention.
One preventive approach targets the ‘Mendelian subsets’ found 
within many MDs. These are single gene disorders (SGDs) that, 
although uncommon, are important because of the high disease 
burden for affected individuals and families: disease is often early 
onset and inheritance usually autosomal dominant. Examples include 
familial hypercholesterolaemia, and hereditary breast and ovarian 
cancer (HBOC) due to BRCA1 and BRCA2 gene mutations.
The primary caregiver should be alerted to a possible SGD by 
the family history or atypical features such as early onset. Further 
assessment follows a standard clinical genetic/genetic counselling 
approach. In the case of suspected HBOC, a risk assessment is 
conducted to decide if the cost of BRCA testing is warranted, and 
includes a detailed family history. Initial genetic testing is best offered 
to an individual with cancer – detection of a disease-causing mutation 
may modify treatment offered, and allows other family members to 
consider testing to predict their risk. In the well publicised case of 
Angelina Jolie, genetic counselling and testing for BRCA mutations 
may have come too late to save her mother, but did allow her to make 
difficult but potentially life-saving decisions regarding risk-reducing 
surgery. 
In view of the personal and family implications of such SGDs, it is 
essential that the tests have excellent clinical validity (high sensitivity 
and specificity) and be provided in the context of genetic counselling 
by a clinical geneticist, genetic counsellor or other appropriately 
skilled health professional.[4]
The article by Schoeman et al.[1] describes an approach to detection 
of BRCA-related breast cancer in a local public health sector 
setting. The article is probably the first local description of a large-
scale, long-term genetic counselling and testing service that is 
rooted in mainstream clinical practice rather than in molecular 
genetic research. The approach aims to maximise accessibility and 
cost-effectiveness of testing while still providing effective genetic 
counselling. Important features include: targeting individuals with 
cancer rather than the ‘worried well’; use of local criteria for offering 
testing; a tiered approach to testing, with the cheaper first tier targeted 
at locally common mutations; adaptation of genetic counselling to 
local circumstances with the genetic counsellor focusing especially 
on positive result feedback and family follow-up; and integration 
of the genetics professional into the multidisciplinary team. Despite 
rationing of tests, the overall BRCA mutation detection rate of 2.6% 
(and 16% of those tested) is credible.
For the remaining majority of MDs, it is increasingly clear that 
the genetic component of susceptibility is usually very complex, with 
many genetic loci and even more genetic variants being involved, and 
a large contribution from environmental factors. In this context, few of 
the genetic variants detected in genome-wide association studies have 
clinically useful predictive value for disease in a given individual. Even 
large panels of genetic variants lack clinical validity or utility.
The article by Dandara et al.,[2] from the committee of the Southern 
African Society for Human Genetics (SASHG), recounts mainstream 
genetic opinion on direct-to-consumer (DTC) testing. It focuses 
primarily on testing for genetic susceptibility to MDs and highlights 
the lack of proven clinical validity and utility of most such tests. Like 
the article, this editorial makes no attempt to address the full range 
of DTC genetic tests. 
A deficiency in the article is its definition of DTC testing as taking 
place ‘without a healthcare provider being involved’ – this excludes 
the situation where the test is advertised as DTC, but a healthcare 
provider (usually without a genetic qualification) is involved in 
the process. In fact, if a test makes ‘health claims’ but lacks clinical 
validity, it should not be offered in any healthcare setting. In the case 
of research, the research component should be clearly demarcated 
and receive specific consent. 
As previously discussed, testing for genetic variants that cause SGDs 
warrants counselling by a genetically-skilled healthcare professional. 
This needs to be taken seriously by DTC companies offering testing 
panels that include known disease-causing mutations (some local DTC 
companies do refer for genetic counselling in this situation). 
In some cases DTC tests are marketed for ‘recreational’ rather than 
health purposes, on the basis that people have a right to explore their 
own genomic information. However, the authors’ recommendations 
for provision of clear information and access to genetic counselling 
are important if there is potential for detecting variants with health 
implications.
Unlike many countries, SA lacks legislation to specifically regulate 
‘medical devices’ (including diagnostic tests) in general. In this 
context, the authors’ suggestion that DTC genetic testing be reviewed 
by the Department of Health would perhaps be better placed as 
part of a broader review process. If the SASHG deems DTC testing 
a priority, an alternative approach is provided by the Consumer 
Protection Act, which allows interested parties to address specific 
issues directly with the Consumer Commission or Tribunal.[5] 
In summary, genetic healthcare professionals have an important 
role in both the implementation of new genetic tests and the 
gatekeeping process, at the dawn of the new genomic diagnostics era.
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